{"entity":{"id":"mipletamig","kind":"drug","name":"Mipletamig","aka":["APVO436"],"tldr":"Mipletamig is a two-armed protein from Aptevo Therapeutics that holds a leukaemia cell and a T cell together so the T cell kills it. It is in an early trial with standard drugs in newly diagnosed acute myeloid leukaemia.","summary":"Mipletamig is a CD123 x CD3 T cell engager from Aptevo Therapeutics. After phase 1 dose escalation and expansion, Aptevo is running RAINIER, a phase 1b/2 dose-optimisation trial started in August 2024 in frontline acute myeloid leukaemia, combining mipletamig with venetoclax and azacitidine in patients unfit for intensive chemotherapy, to set a recommended phase 2 dose. The company reports favourable initial results; they are its own.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"SEC: Aptevo Therapeutics Form S-1, August 2026","url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526361103/apvo-20260821.htm"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["t-cell-engager"],"targets":["cd123","cd3"],"drugs":[],"companies":["aptevo-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The code APVO436 is the name under which the molecule was earlier reported; the August 2026 filing uses mipletamig."],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"modality":"Bispecific T cell engager","mechanism":"A CD123 x CD3 bispecific protein built on Aptevo's ADAPTIR platform, with a CRIS-7 CD3-binding domain, that redirects T cells to kill CD123-expressing leukaemia cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mipletamig/","neighbours":{"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd123","kind":"target","name":"CD123","route":"/targets/cd123/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"company":[{"id":"aptevo-therapeutics","kind":"company","name":"Aptevo Therapeutics","route":"/companies/aptevo-therapeutics/"}]}}